Item 8.01 Other Events.

On January 31, 2023, the board of directors of PharmaCyte Biotech, Inc. (the "Company") authorized a share repurchase program to repurchase up to $10 million of the Company's outstanding common stock (the "New Program"). The New Program is effective immediately for a two-year period. The Company expects to fund the program with its available cash. The Company enacted a similar program in June 2022 (the "Existing Program"), and as of the date hereof, the Company has repurchased 3,410,624 shares of common stock for an aggregate purchase price of approximately $9.3 million under the Existing Program.

Under the New Program, the shares may be repurchased from time to time in open market transactions, privately negotiated block transactions, or other means in accordance with applicable securities laws. The timing of the purchases, the number of shares repurchased, and the prices paid for the shares under the New Program will depend on general business and market conditions, the trading price of the Company's common stock and corporate and regulatory limitations, including blackout period restrictions. The New Program does not obligate the Company to acquire a specific dollar amount or number of shares and may be extended, modified, or discontinued at any time.

On February 2, 2023, the Company issued a press release announcing the authorization of the New Program. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits.

Number Description 99.1 Press Release, dated February 2, 2023, of PharmaCyte Biotech, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).












  2

© Edgar Online, source Glimpses